Adults over 50 facing polymyalgia rheumatica may soon have a critical alternative to prolonged corticosteroid therapy, which carries substantial risks including bone loss, diabetes progression, and cardiovascular complications. This inflammatory condition affecting shoulders, neck, and hips has lacked effective steroid-sparing options for decades.
Secukinumab, an interleukin-17A inhibitor already approved for psoriasis and ankylosing spondylitis, demonstrated significant efficacy in maintaining PMR remission while allowing corticosteroid reduction. The phase 3 randomized controlled trial enrolled patients who had achieved initial disease control with prednisone, then compared secukinumab against placebo during steroid tapering. The primary endpoint measured sustained remission at week 52 with successful corticosteroid withdrawal.
This represents a meaningful advance in rheumatology care, as PMR typically requires 12-24 months of corticosteroids, often causing debilitating side effects in an already vulnerable older population. The IL-17A pathway's role in PMR pathogenesis had been suspected but not definitively targeted therapeutically until now. While secukinumab's safety profile is well-established from other indications, its cost-effectiveness for PMR will require careful health economic evaluation. The trial's design focusing on steroid reduction rather than initial treatment reflects pragmatic clinical reality, though questions remain about optimal timing of biologic introduction. This study could reshape PMR treatment paradigms if regulatory approval follows, offering hope for the estimated 700,000 Americans living with this condition. However, the relatively small patient population and specialized monitoring requirements may limit immediate widespread adoption.